Apotex minutes late on potassium CGT

Apotex missed by a matter of minutes its opportunity to block competition to the Canadian company’s potassium chloride 10% oral solution in the US, the US Food and Drug Administration (FDA) has determined. Therefore, the agency denied Apotex’ request to rescind approval for Novel Laboratories’ abbreviated new drug application (ANDA) for an alternative to Genus Lifesciences’ reference drug.